US vascular devices maker Boston Scientific has presented the results of an analysis of the HORIZONS AMI trial on the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in patients experiencing acute myocardial infarction, at the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics symposium in Washington DC.
One-year results from the 3,006-patient, prospective, large, international, randomized clinical trial comparing the Taxus system with a bare-metal stent, showed comparable overall safety outcomes (death, stroke, myocardial infarction or stent thrombosis) between the two treatment groups (8.0% for the bare-metal stent versus 8.1% for the TAXUS stent, p=0.92). There was a statistically-significant 41% reduction in revascularization in the TAXUS group (7.5% for the ordinary stent vs 4.5% for TAXUS, p=0.002). Subjects will be followed for five years to ensure that the results are maintained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze